Emerging links between cerebrovascular and neurodegenerative diseases—a special role for pericytes

Urban Lendahl¹,²,³, Per Nilsson² & Christer Betsholtz⁴,⁵,*

Abstract

Neurodegenerative and cerebrovascular diseases cause considerable human suffering, and therapy options for these two disease categories are limited or non-existing. It is an emerging notion that neurodegenerative and cerebrovascular diseases are linked in several ways, and in this review, we discuss the current status regarding vascular dysregulation in neurodegenerative disease, and conversely, how cerebrovascular diseases are associated with central nervous system (CNS) degeneration and dysfunction. The emerging links between neurodegenerative and cerebrovascular diseases are reviewed with a particular focus on pericytes—important cells that ensheathe the endothelium in the microvasculature and which are pivotal for blood–brain barrier function and cerebral blood flow. Finally, we address how novel molecular and cellular insights into pericytes and other vascular cell types may open new avenues for diagnosis and therapy development for these important diseases.

Keywords: blood–brain barrier; cerebrovascular disease; neurodegenerative disease; neurovascular unit; pericyte

Introduction

The brain and its vasculature

The human central nervous system (CNS) is composed of 100 billion neurons connected in intricate ways. In addition, there is an even larger number of supporting glial cells, i.e., astrocytes and oligodendrocytes, the latter forming myelin sheets around neurons and making up a large part of the white matter in the brain. Another important cell category is the microglia—macrophage-like cells important for scavenging cellular debris and protein aggregates, but when activated they also become central players in brain inflammation. While neurons and glial cells traditionally have been classified into subcategories based on morphological and anatomical criteria or differences in neurotransmitter repertoire, a new and more fine-grained view of neurons and glial cell sub-types is now emerging as a result of recent transcriptomic analyses of the brain at the single-cell level. Thus, more than 500 molecularly distinct classes of neurons and glial cells have been identified in the mouse brain [1,2], and information about the cellular composition of specific brain regions is increasing rapidly [2–8]. Insights into the developmental trajectories for the different cell lineages—proceeding from immature progenitors to specialized cells—are generated by computational analyses of single-cell transcriptomes derived from different developmental stages [8–10]. Most data thus far are derived from the mouse, but progress is made in understanding cell type diversity also in the human brain [10]. With the available data from the normal unperturbed situation as a benchmark, gene expression changes related to diseases now start to be elucidated, for example, in Alzheimer’s disease (AD) [11] and multiple sclerosis [12], where single-nuclei RNA sequencing technology has been used to capture transcriptomes at single-cell resolution. It is expected that several additional diseases, in particular those that can be faithfully recapitulated in mouse models, will be transcriptomically analyzed in a not too distant future.

The brain constitutes ≈2% of the adult human body weight but receives 20% of the cardiac output and consumes 20% of our oxygen and glucose. However, it has almost negligible capacity for long-term storage of energy and is therefore dependent on an elaborate vasculature that continuously fuels the brain with oxygen and nutrients. The vasculature of the brain has an intricate architecture: Feeding arteries follow the outer rim of the brain via the meninges and make branches that penetrate perpendicularly into the brain parenchyma (sometimes referred to as penetrating arterioles), where they further split into smaller arterioles and eventually into capillaries (Fig 1A–C). The capillaries subsequently join into venules that collect into radially oriented veins that further drain into the veins of the arachnoid (Fig 1D).

Keywords: blood–brain barrier; cerebrovascular disease; neurodegenerative disease; neurovascular unit; pericyte

DOI 10.15252/embr.201948070 | Received 12 March 2019 | Revised 11 June 2019 | Accepted 24 June 2019 | Published online 16 October 2019

EMBO Reports (2019) 20: e48070

See the Glossary for abbreviations used in this article.

1 Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
2 Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Center for Alzheimer Research, Karolinska Institutet, Solna, Sweden
3 Integrated Cardio Metabolic Centre (ICMC), Huddinge, Sweden
4 Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
5 Department of Medicine, Karolinska Institutet, Huddinge, Sweden
*Corresponding author. Tel: +46 709 796690; E-mail: christer.betsholtz@ki.se
The blood vessels are built from two principal cell types: an inner lining of endothelial cells surrounded by an outer layer of mural cells. The mural cells have different phenotypes and are called by different names depending on vessel type: vascular smooth muscle cells (VSMC) cover arteries, arterioles, and veins, and pericytes cover capillaries and venules (Figs 1D and 2). The proportion of abluminal endothelial cell surface covered by mural cells varies among vessel types. The coverage is almost complete in arteries and larger veins, whereas it is incomplete in microvessels. The least pericyte coverage (≥10–20%) is observed in capillaries, where (in the brain) the pericytes are typically bipolar (sometimes tripolar at capillary branch points) and stretch two primary processes along the length axis of the capillary. From the primary processes, short sawtooth-like secondary processes extend.

For the most part, the interface area between the pericytes and endothelial cells is physically separated by basement membrane. However, at specialized sites, often located at the end of secondary processes, the pericyte and endothelial cell membranes come into close apposition. These sites are referred to as peg-socket contacts and adhesion plaques. In the peg-socket contacts, pericytic cytoplasmic projections (“pegs”) protrude into endothelial membrane pockets (“sockets”), whereas the adhesion plaques are flat areas of contact. An important question related to both of these contact types is if one pericyte contacts one or more endothelial cells, thereby potentially integrating their functional behavior. The peg-socket structures have thus far mostly been observed at the ultrastructural level in transmission or scanning electron microscopy analysis of animal tissues [13,14], but they also seem to form under in vitro conditions during pericyte–endothelial cell co-culture [15]. Little is, however, known about the physiological role of the peg-socket contacts, but it is an intriguing possibility that these structures harbor gap junctions and possibly also other moieties involved in contact-dependent (“juxtacrine”) signaling [16] (Fig 1D). Although the pericyte:endothelial ratio in the brain is high compared to other organs, and sometimes claimed to be in the order of 1:1, our own unpublished observations suggest that the brain pericyte density is severalfold lower than that of endothelial cells. Therefore, from the fact that the contact between the capillary tube and pericytes in the brain is close to 100% (i.e., one would find a pericyte–endothelial interface area in every capillary cross-section) follows that one pericyte contacts several endothelial cells [Fig 1B]. Since pericytes are difficult to distinguish from other perivascular cell types using light microscopy based on singular protein or mRNA markers, the peg-socket contacts may constitute a defining criterion for pericytes versus other perivascular cell types, including perivascular fibroblasts and macrophages. Progress in understanding pericytes and endothelial cells at the proteomic and transcriptomic levels may provide ideas for cytoskeletal and other proteins that reside in the peg-socket contact and adhesion plaques.

The blood–brain barrier

A particular feature of the brain vasculature is the blood–brain barrier (BBB), which serves to separate the blood from the extracellular fluids of the brain (interstitial and cerebrospinal fluid; ISF and CSF, respectively) and hinders pathogens and xenobiotic substances from entering the brain. The non-fenestrated endothelial cells in the brain vasculature are interlocked via tight junctions and adherens junctions, forming a tight physical barrier. This contrasts with the endothelium in, for example, the liver, kidney, and endocrine organs, which is fenestrated and therefore freely permeable for solutes and small proteins. To allow for efficient, precise, and regulated transport of ions, sugars, amino acids, nucleic acids, lipids, and proteins, the BBB is equipped with a wide range of specific influx transporters, as well as receptors that engage in receptor-mediated transcytosis. In addition, in order to bounce off unwanted and potentially neurotoxic substances present in the blood, including xenobiotics taken up from the gut, the BBB endothelium also
expresses several efflux transporters that nonspecifically recognize and export small lipophilic molecules. This feature of the BBB is a major barrier against low molecular weight pharmaceuticals and poses a problem for efficient drug delivery to the brain.

Whereas the specific features of the BBB described above mostly can be attributed to the endothelial cells, surrounding peri-endothelial cells also play important roles as inducers and regulators of the BBB properties of endothelial cells as well as by taking active part in the homeostatic functions of the BBB. The latter is suggested by the many transporter molecules that are specifically expressed in brain pericytes as compared to lung pericytes [17]. Among the different types of peri-endothelial cells, including immune cells, fibroblasts, and—depending on the organ—epithelial cells, the pericytes deserve special attention because they appear to be a ubiquitous and obligatory component of the microvessel wall. As mentioned, the CNS harbors pericytes at higher density than in peripheral organs, for example, in skeletal muscle, where the ratio of pericytes to endothelial cells has been suggested to be a hundredfold lower than in the CNS (for review, see ref. [18]). While the magnitude of the reported differences should be treated with caution since pericyte identification remains ambiguous, it appears that the pericyte density in the CNS is high enough to allow for contact with every (or at least the vast majority of) endothelial cell. The BBB integrity also depends on astrocytes, which almost completely encapsulate the vasculature with their endfeet [19] (Figs 1B and 2). Regulated transport across the endothelial layer in the BBB is largely driven by transcytosis in the endothelial cells, and as discussed below, the molecular underpinnings of controlled BBB permeability, and the role of pericytes, are intense areas of research.

Platelet-derived growth factor signaling is critical for pericycle recruitment, differentiation, and homeostasis [18]. Hence, evidence for the importance of pericytes for BBB integrity has been largely provided from analyses of mouse models with hypomorphic PDGF signaling [20,21]. One such model, the Pdgfrb<sup>-/-</sup> mouse, produces only a truncated PDGF ligand (PDGFB-ret) lacking a C-terminal stretch of amino acid residues referred to as the retention motif. This motif mediates binding of the secreted PDGFB wild-type molecule to proteoglycans on the cell surface or in the extracellular matrix [22]. Truncation of the retention motif makes PDGFB-ret unable to bind proteoglycans. While the PDGFB-ret molecule retains its full capacity to activate the PDGF β-receptor (PDGFR-β), the increased diffusion of the PDGFB-ret molecule away from its producer cells—the endothelium—presumably lowers its active concentration in the pericyte vicinity. In other models, the Pdgfb or Pdgfrb genes have been fully or partially ablated. In Pdgfb and Pdgfrb null mutants (heterozygous or homozygous) as well as in the Pdgfb<sup>-/-</sup> mouse, there is a reduction in pericycle numbers, coupled with BBB dysfunction and leakage as well as defects in endothelial transcytosis [20,21,23]. More recent studies have demonstrated that the BBB leakage in the Pdgfb<sup><sup>-/-</sup></sup> mice differs in different brain regions [24]. Pericycle loss has also been studied in another PDGF-signaling impaired mouse model, the Pdgfrb<sup>F7/F7</sup> mouse, which reduces signaling competence on the receptor side [25]. In the Pdgfb<sup>F7/F7</sup> mice, both pericytes and VSMC are affected, but BBB breakdown was observed in the Pdgfrb<sup>F7/F7</sup> mice at the stage when only pericytes were affected, indicating that the BBB impairment in these mice develops as a result of the loss of pericytes, rather than due to loss of VSMC [26].

Pericytes and endothelial cells are engaged in a complex cross-talk, which is only partially understood. There are several ligand–receptor interactions operating between pericytes and endothelial cells, including PDGF-PDGFR, Ang1-Tie-2, and TGFβ signaling [18]. The Notch signaling pathway is also involved, notably by regulating PDGFR-β expression in pericytes and VSMC [27]. Accordingly, Notch signaling is pivotal for the integrity of pericytes and VSMC [27–29]. Recent work has also implicated CD146 (MCAM) in pericyte recruitment, potentially as a co-receptor for PDGFR-β [30]. While these and other studies [31] clearly show that the loss of pericytes impairs the formation of vascular barriers in the CNS, activated or perturbed pericytes may also do harm to the CNS vasculature [32]. It has, for example, been demonstrated that the specific ablation of the TGFβ receptor ALK5 in pericytes causes brain hemorrhage in developing mouse embryos, but does so without depleting pericyte number [33]. This suggests that modulation of a specific gene function in pericytes can result in a more severe phenotype than that observed in the complete absence of pericytes [34]. Thus, pericycle dysfunction may have worse consequences for the BBB than pericyte dropout.

The complex role of pericytes at the BBB is underscored by studies of mice with reduced pericycle numbers, such as the above-mentioned Pdgfb<sup>-/-</sup> mice, which nevertheless eventually develop a seemingly stable pericycle-deficient brain vasculature with specific attenuation of the endothelial transcytosis barrier [20]. The mechanism(s) involved in the transcytosis process activated by pericycle hypoplasia are unknown, however, and while insights into receptor-mediated transcytosis mechanisms across brain endothelial cells were recently provided by a study revealing a system of intracellular tubules that control transport across the endothelial cell [35], it is unclear whether loss of pericytes affects this system. To what extent pericytes affect other aspects of the BBB, such as the endothelial junctions, is also unclear. Tight junction proteins such as claudins, and in particular the endothelial-specific claudin 5 (Cldn5) [36], are important for BBB integrity and limit paracellular transport via interlocking endothelial cells by tight junctions (for review see ref. [37]). Available data on whether pericycle loss (caused by the above-mentioned Pdgfb and Pdgfrb mutants) leads to changes in Cldn5 expression are partly inconsistent [20,38] and the topic therefore requires further study.

The brain needs to rapidly increase oxygen and nutrient supply to the brain areas that at a given point of time are most active.
Thus, the local cerebral blood flow (CBF) needs to be constantly adjusted to increase blood flow to active brain regions. The neurovascular unit (NVU), which is a conglomerate of endothelial cells, pericytes, VSMC, astrocytes, and neurons, is an important regulator of CBF (Fig 2). The connection between neuronal activity and CBF, which allows for the adjustment of CBF in response to the extent of neuronal activity, is referred to as neurovascular coupling (a.k.a. functional hyperemia). The specific roles of the various vascular cell types in CBF regulation are only partially understood, and several cell types have been implicated in neurovascular coupling. There are studies advocating regulatory roles for pericytes [39–41] (for review see ref. [42]), astrocytes (although via pericytes) [43] as well as VSMC [44]. Erythrocytes themselves may also influence CBF via oxygen sensing of their own deformability [45].

These divergent views suggest that a deeper molecular understanding of pericytes and other cell types in the brain vasculature is warranted. The first transcriptomic maps of vascular cells were generated by RNA sequencing at the cell population level [46–48]. More recently, single-cell RNA-sequencing (scRNA-seq) was used to provide transcriptional profiles for pericytes and all other brain vascular cell types, as well as for astrocytes and microglia [17]. The single-cell transcriptomes of brain endothelial cells reveal a graded transcriptional zonation from the arterial to the venous side, which matches with the gradual change in vessel diameter and presumed changes in biophysical parameters such as pressure and shear, and chemical composition of the blood such as level of oxygenation, that takes place along the arterio-venous (A-V) axis. In contrast to the gradual transcription changes in endothelial cells, mural cells showed a more distinct zonation pattern along the A-V axis. Here, pericytes constitute a quite distinct cell population, well-separated from arterial and arteriolar VSMC transcriptional profiles, but with a gradual phenotypic conversion into venous VSMC. An intriguing finding was the abrupt transition from the arteriolar SMC phenotype to a capillary pericyte phenotype from one cell to the next at the border between a terminal arteriole and the following capillary [17]. Previous reports have shown that pericytes in the mouse brain exhibit distinct morphologies depending on their location: a pericyte located on the capillaries is, for example, morphologically distinct from a pericyte on the postcapillary venules (for reviews see refs. [18,49]; Fig 2). It was therefore an unexpected finding that the brain pericytes in the scRNA-seq study constituted a molecularly homogenous population of cells without signs of molecular subtypes [17]. The apparent discrepancy between transcriptional homogeneity and morphological heterogeneity of pericytes is not understood. The pericytes in the scRNA-seq study were captured from different brain regions via a dual reporter system (fluorescent reporters driven by PDGFRβ and NG2 regulatory elements) [17], and although dual-labeled pericytes can be identified in all main areas of the brain, it remains possible that some subpopulations were not efficiently captured by this strategy. Alternatively, some pericyte populations may fare less well in the sorting and enrichment procedures, leading to underrepresentation in the
transcriptome data set. With the advent of new pericyte markers [17], the question of heterogeneity can now be systematically addressed. Furthermore the discovery of novel ways to specifically stain pericytes, for example by Neurotrace 500/52 [50], may allow for complementary scRNA-seq explorations of brain pericyte transcriptomes. The pericyte scRNA-seq analysis revealed discrepancies between certain mRNA species and the reported expression levels of the cognate protein. Notably, expression of α-smooth muscle cell actin (α-SMA) (Acta2) mRNA was very low in brain pericytes, which adds to the active discussion on the distribution and role of α-SMA in pericytes. While some reports fail to detect α-SMA immunoreactivity in the pericytes of a healthy mouse CNS [17,44], other reports have identified α-SMA immunoreactivity [51–53] as well as reporter gene activity driven from the α-SMA promoter [44] in brain pericytes. α-SMA levels may differ depending on pericyte location: pericytes closer to the arteriolar side may express higher α-SMA levels, while pericytes at the center of the capillary bed express less α-SMA [51]. It has also been proposed that α-SMA is rapidly degraded during sample preparation, which may be a reason why it is not detected by immunohistochemistry in all situations [54]. The reason for the very low level of α-SMA mRNA expression from the transcriptomic analysis versus higher protein levels observed by immunohistochemistry remains to be explored, and such information will be important for the understanding of the putative contractile properties of pericytes.

Paravascular flow

In addition to the vascular system proper, there is a second major important fluid-transporting system in the brain—paravascular flow—regulating the flow of CSF and ISF in the brain parenchyma (Fig 1). CSF is generated in the choroid plexus, transported via the subarachnoid space in the meninges, and drained via specialized connections to veins and lymphatic vessels present in the dura mater [55]. The subarachnoid space is continuous with the brain’s perivascular spaces (PVS), thin cavities that surround and follow the penetrating (parenchymal) arteries and veins [56,57] (Fig 1D). The PVS are important for water, solute, and waste product exchange between the CSF and ISF. How the paravascular flow is regulated is only partially understood, but cerebral vascular basement membranes are important as conduits for fluid transport into and out of the brain [58]. Furthermore, a recent report shows that experimental damage to the meningeal lymphatic system leads to accumulation of protein aggregates in the brain parenchyma including both AD-associated amyloid β peptide (Aβ) [55] and tau [59], indicating that ISF and CBF drain to the meningeal lymphatics. An alternative system for paravascular flow is the glymphatic system, which has been proposed to be important as a removal system for products such as lactate, Aβ, and tau [60]. In the glymphatic system, astrocytes are important for ion buffering and fluid exchange between the CSF and ISF, and it has been proposed that glymphatic clearance is higher in the sleep state [61]. From this follows that sleep might be required for “waste” removal from the brain. The exchange through the glymphatic system has been suggested to be dependent on the water channel aquaporin-4 (Aqp4) present in the astrocytic endfeet (Fig 3A). The role of Aqp4 in glymphatic function is, however, still a matter of discussion. The development of a functional glymphatic system in mice was shown to be correlated with the expression of Aqp4 at the astrocyte endfoot–vascular interface [62], and using several lines of Aqp4-deficient mice, glymphatic tracer transport was shown to depend on intact Aqp4 function [63]. It has, however, also been argued that Aqp4 may not be solely responsible for fluid transport, but that diffusion is in fact an important regulator of paravascular flow. In support of this notion, CSF tracer uptake and interstitial flow rate were unaffected by cardiac arrest or ablation of the Aqp4 gene [64]. Diffusion-driven transport of injected tracers was also noted by several other studies [65–68] (for review see [69]). Tracer flow does not connect to perivascular drainage, and studies of the routing of tracers show that tracers injected into the CSF enter along pial-glial membranes but exit the brain along VSMC basement membranes, going against the direction of blood flow [70]. In addition, levels of ISF and CSF tau relate to neuronal activity and the sleep–wake cycle rather than to paravascular clearance [71]. It has also been shown that the majority of Aβ removal (85%) occurs via the BBB and only a minority via ISF bulk flow in mice [72,73], and similar findings are reported from humans [74]. From these partially conflicting views on how paravascular flow is organized, and the role of the glymphatic system, it is clear that more research is required to understand in detail how fluid transport in the brain is regulated in the healthy and diseased states.

Do pericytes play a role in the glymphatic system? A recent analysis of pericyte-deficient Pdgfrαret/ret mice shows a defective development and persistence of glymphatic function, suggesting that PDGFB signaling plays an important role in the development of the glymphatic system [62]. It is likely that this role is mediated by pericytes, since the local absence of pericytes in Pdgfrαret/ret mice correlates with relocation of Aqp4 from astrocyte endfeet to the astrocyte cell soma at these sites [20]. However, it should be kept in mind that the development of the vasculature in the Pdgfrαret/ret mice is more generally altered, including capillary dilation and impaired BBB function [20]. Thus, pericytes may not only locally influence the endothelial cells, but may also interact with and regulate functions in neighboring astrocytes. Pericytes highly express laminin-α2 (Lama2), laminin-β1 (Lamb1), and laminin-γ1 chains (Lamc1) [17] (Fig 3B), which, as part of laminin 211 deposited in the vascular basement membrane, is known to bind the dystrophin–glycoprotein complex in astrocytes, which in turn acts as a molecular bridge to Aqp4, promoting its concentration at the astrocyte endfeet [75] (Fig 3A). In keeping with a role for pericytes in the polarization of Aqp4 to astrocyte endfeet, knockout of the Lama2 gene in mice causes BBB abnormalities and loss of Aqp4 polarization to astrocyte endfeet [76], similar to the situation reported in pericyte-deficient

Figure 3. Pericytes and the glymphatic system.

(A) A schematic model for the interaction between pericytes and the glymphatic system. The figure shows that pericytes (PC) and perivascular fibroblasts (FB) express Lama2, Lamb1, and Lamc1, which encode the subunits of laminin 211. Laminin 211 interacts with dystrophin in astrocytes. This leads to the concentration of aquaporin 4 (Aqp4) in the astrocytic endfeet, which is important for the fluid transport and the function of the glymphatic system. (B) The mRNA expression profiles for Lama2, Lamb1, and Lamc1 (from http://betsholtzlab.org/VascularSingleCells/database.html [17]) are depicted.
Figure 3.
mice. Thus, several studies support a scenario in which pericytes influence the development of the lymphatic system through deposition of laminin 211 in the vascular basement membrane, which via dystroglycan and dystrophin in astrocytes promotes polarization of Aqp4 to its endfeet.

In addition to molecularly defining the different mural cell subtypes, the scRNA-seq analysis of the brain vasculature also identified a novel fibroblast-like cell type—the perivascular fibroblast—with a localization close to or within the PVS [17] (Fig 1D). These cells differ from mural cells by their expression of PDGF receptor alpha and numerous extracellular matrix proteins in common with lung fibroblasts, including the fibrillar collagens 1,3, and 5, lumican, decorin, and others. They also deposit specific extracellular matrix (ECM) proteins, including laminin-α1 (Lama1), which helped pinpointing the exact localization of these cells, namely surrounding arteries, arterioles, venules, and veins, but notably not around the capillaries. The localization of the perivascular fibroblasts along the PVS may be of relevance for paravascular flow, as certain aspects of the flow occur along vascular basement membranes (see above). An intriguing notion is that the perivascular fibroblasts reside between the two basement membranes—the astrocyte-derived pial basement membrane and the basement membrane embedding the arteriolar and arterial VSMC—implicated in inward (arachnoid-to-brain) and outward (brain-to-arachnoid) tracer transport, respectively, indicating a possible role for the perivascular fibroblasts in the separation and compartmentalization of these tightly apposed transport routes [70]. Notably, the perivascular fibroblasts abundantly express Lama2, Lamb1, and Lami1, thereby perhaps also playing a role in astrocyte endfoot polarization around larger vessels, similar to the role of pericytes in the capillaries. The Lama1-positive adventitial coat was independently observed in a recent study, although with a more restricted distribution on the venous side [77], and this difference in distribution should also be addressed in future studies. The localization of the perivascular brain fibroblasts along the PVS is also interesting in the light of cerebral small vessel disease (SVD) (see below). Expression of transporter proteins in the perivascular brain fibroblasts [17] may play a role in fluid composition and dynamics in the CSF and ISF and in the apposed opposite paravascular transport routes discussed above. Cells with a transcriptome profile closely resembling the perivascular brain fibroblast have been observed in other transcriptomic analyses of brain cells [2,6] and additional, but not yet fully characterized, fibroblast subtypes have been identified [2,17], indicating a broader fibroblast landscape within and around the CNS. It will be of interest to establish whether cells with characteristics similar to the perivascular brain fibroblast exist in the human brain. Earlier electron microscopy (EM) studies of human meningeal blood vessels [78] reveal a cell type with similar location and morphological characteristics, suggesting this to be the case, but a more detailed molecular analysis has not yet been performed.

Neurodegenerative diseases and the brain vasculature—an emerging relationship

There is an emerging view that neurodegenerative diseases are characterized not only by decaying neuronal cells but also by vascular aberrations, and conversely, that diseases with an origin in the brain vasculature affect the surrounding CNS. To establish whether the CNS and vascular phenotypes represent incidental co-occurrences or whether there are casual relationships between a dysfunctional CNS and problems in the brain vasculature is an important topic to address, with high relevance for understanding the pathobiology of the disease and to develop novel therapeutic strategies.

Neurodegenerative diseases affecting the vasculature

Neurodegenerative diseases cause considerable human suffering and societal costs, and their incidence is increasing because of the aging population. In neurodegenerative diseases, specific types of neurons are lost, and insights into the underlying molecular pathology are rapidly accumulating. AD is characterized by loss of neurons and synapses in the cerebral cortex and hippocampus, and accumulation of Aβ peptide (from aberrant processing of the amyloid-precursor protein (APP)) and tau in neurofibrillary tangles are hallmarks for AD. In a minority of patients, mutations are found in presenilin and APP genes, but most cases are sporadic, with a specific APOE allele (APOE4) as risk factor [79]. Although the neuronal loss is a major factor for the cognitive decline, it is becoming increasingly appreciated that AD also has a vascular component [80–83]. At the ultrastructural level, pericytes are disorganized in AD and exhibit mitochondrial abnormalities, pinocytotic vesicles, and accumulation of osmophilic material [84,85], which may impair BBB function. Furthermore, AD patients, as well as AD mouse models, show pericyte loss, which correlates with the extent of BBB degradation [86,87]. BBB breakdown is accelerated in AD [88] and is also observed in mild cognitive impairment (MCI) [89,90]. Overall, at least 40% of AD patients have pronounced vascular changes, and many of these patients will be diagnosed with a mixed type of dementia [91–93]. Wolters et al [94] have unraveled links between cerebral perfusion and the risk of dementia. In line with this, CBF is reduced in AD [95–97], which may be attributed to morphological changes in capillaries [98,99]. A decline in the number of pericytes may be observed not only in the diseased condition but may be a part of the normal aging process, as BBB breakdown and pericyte loss increase in the aging hippocampus [89]. The pericyte decline is linked to an increase in the levels of soluble PDGFRβ in CSF, and elevated soluble PDGFRβ levels in CSF are an early independent biomarker of cognitive dysfunction, irrespective of Aβ and tau status in the CSF [90]. A consequence of the deterioration of pericytes and loss of BBB integrity is an increased influx of immune cells into the brain, which in turn drives inflammation, an important disease-promoting factor in neurodegenerative as well as cerebrovascular disease [for review see [100]]. In addition to a role in BBB integrity, pericytes may be important for clearing aggregated Aβ, as pericyte loss leads to elevated Aβ levels, presumably by reducing clearance of Aβ from the ISF [87]. Aβ may, however, also be toxic to pericytes [101], notably with an increased vulnerability if the pericytes are of the ApoE4 genotype. The ApoE expression levels are allele-specific with the lowest being for ApoE4 [102], Pericytes can take up Aβ via LRP1 receptors, and the LRP1-mediated uptake was inhibited by blocking pericyte ApoE production. The blocking could be rescued by supplementing with exogenous ApoE3 but not ApoE4 [103], which is interesting given the role of the APOE4 allele as risk factor in AD. App transgenic mice exhibiting high levels of Aβ40 show defects in vasodilatory response revealing that Aβ40 has toxic
effects on the vascular system [104]. The increased Aβ levels in AD lead to Aβ deposits not only in the brain parenchyma but also at the vessel wall in cerebral amyloid angiopathy (CAA). CAA, which is classified as an SVD (see also below), was found in more than 80% of all AD cases. However, Aβ deposits in the vascular system are also observed during normal aging process but for unknown reasons do not induce pathology (reviewed in ref. [105]). CAA occurs in the neocortical and leptomeningeal arteries as well as in capillaries [106] and shows an increased Aβ40/42 ratio, which is different from that in Aβ deposits in the parenchyma, indicating a vascular-specific mode of aggregation. Importantly, the Dutch, Iowa, Arctic, Flemish, and Italian familial autosomal dominant mutations in the APP gene, which change the Aβ sequence at amino acid 22, induce a strong CAA characterized by pronounced Aβ40 deposits in the vessel walls (reviewed in ref. [107]). Interestingly, the CAA pathology has recently been recapitulated in App knock-in mice harboring the Dutch mutation [108], indicating that further insights may be provided from animal experiments. Similar to the CAA and AD situation in humans, these mice exhibited microhemorrhages and reduced CBF. Transverse aortic constriction of the left common carotid artery to reduce blood flow to the brain of the knock-in mice significantly enhanced CAA, implicating a tight connection between CAA and CBF.

In APOE4 carriers, CAA is additionally observed in capillaries and frequently in arterioles, and this aggravated form of the disease is referred to as CAA type I [105]. As discussed above, this may be linked to the APOE4 allele-specific vulnerability of the pericytes to Aβ and changes in the transport of Aβ over the BBB. However, astrocytes are also major contributors to ApoE production, and in the presence of CAA, they exhibit pathological changes such as swelling of their endfeet. In severe cases of CAA, an altered ionic and water balance is observed due to changes in potassium and water channels and eventually astrocyte loss will occur [109], which may be aggravated by the extensive neuroinflammation in AD brains. Eventually, CAA leads to degeneration of all vascular cells, including pericytes, which can cause microhemorrhages and infarction thus further aggravating the disease state. There are studies indicating that the vascular phenotype is an early event in the disease process, and that microvascular changes in fact precede cognitive impairment in a mouse model for AD [110]. An early vascular impact is corroborated by data from a recent study identifying early cerebrovascular abnormalities in AD patients [97].

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by loss of motor neurons, and mutations in more than 30 genes, including superoxide dismutase 1 (SOD1), have been identified in the disease [111]. Breakdown of the blood–CNS barrier in the spinal cord, as evidenced by erythrocyte extravasation, is observed in ALS patients, and the number of pericytes can be reduced by almost 50% [112]. It is not yet established whether similar changes occur in the motor cortex of the brain. Vascular problems, in the form of cerebral arteriovenous malformations (AVMs), have been associated with ALS development in a few cases [113], although it remains a possibility that initial treatment of AVMs might induce ALS-like symptoms [114]. Microvascular structures in the retina have been reported to be altered in ALS [115]. ALS patients have elevated PDGFC expression, and activation of the PDGF-CC signaling pathway via PDGFR-α leads to an earlier onset of neurodegeneration in ALS mouse models [116], suggesting that modulation of this signaling pathway may be a potential therapeutic strategy for ALS.

Huntington’s disease (HD) is a neurodegenerative disease caused by mutations in the Huntingtin gene, leading to CAG repeat/polyglutamine expansions [117]. In HD, the expanded huntingtin proteins form protein aggregates in neurons, and basal ganglia, caudate nucleus, and putamen are among the first brain areas to be affected. Spiny neurons are also lost in the striatum. Recently, it has been noted that brain pericytes become activated early in the HD disease process [118], and HD is associated with impaired BBB function and decreased PDGF-β mRNA expression in pericytes [119]. Furthermore, blood–spinal cord barrier leakage is observed in HD patients [120].

In addition to the neurodegenerative diseases, vascular problems are also observed following traumatic brain injury (TBI) and in neuropsychiatric disorders (for review see [121]). BBB disruptions occur in TBI [122,123], which may contribute to the more long-term neurological problems in TBI. This may be linked to pericyte dysfunction as pericyte migration away from the vascular wall was noted after experimental TBI in rats [124]. PDGFRβ-expressing cells, suggested to be pericytes, also increase in numbers in the trauma zone following experimental TBI in mice [125]. In addition, deletion of Agrp4 aggravates the TBI-induced tau pathology in TBI mice, indicating a role for the glymphatic system in the clearance of tau [126]. BBB dysfunction was likewise observed in a boxer suffering from chronic traumatic encephalopathy [127]. Another emerging research area at the neuronal–vascular interface is schizophrenia, a mental disorder with complex underlying genetics. The cause of schizophrenia is not well-understood but may involve disturbed dopamine and NMDA receptor signaling. In addition to the neurological problems, an aberrant microvasculature as well as abnormal CBF is observed in schizophrenia [128–130]. Elevated levels of albumin in the CSF in schizophrenic patients indicate leakage across the BBB [131]. In keeping with a leaky BBB, the level of Cldn5, one of the proteins in the endothelial cell tight junctions in the BBB (see below), was reduced in schizophrenic patients [132].

Cerebrovascular diseases affecting the CNS

In the previous section, we discussed vascular complications in neurodegenerative diseases and specific roles for pericytes in this group of disorders, and we will now review evidence for the converse situation, i.e., vascular diseases giving rise to CNS dysfunction. There is obvious widespread damage to the CNS resulting from a massive stroke, but more confined vascular problems also affect the CNS. An important subgroup of cerebrovascular diseases is the cerebral small vessel diseases (SVDs), which account for approximately 20% of all ischemic strokes. SVDs are characterized by changes in the small vessels in the brain accompanied by enlarged PVS [133,134]. Importantly, damage to cerebral white and deep gray matter is also observed in SVD patients, indicating that the oligodendrocyte lineage and myelin production may be affected. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most frequent monogenic form of SVD and is caused by mutations in the NOTCH3 gene [135], leading to NOTCH3 protein accumulation, white matter lesions (WML), and subcortical infarcts. In CADASIL, the vascular changes appear to precede WML, suggesting a primary origin in the vasculature, which is in line with the fact that NOTCH3 is
predominantly expressed in VSMC and pericytes. Interestingly, another genetic SVD, CARASIL, which is predominantly caused by loss-of-function HTRA1 mutations [136], may be functionally linked to CADASIL, as trapping of the HTRA1 protein, a secreted serine protease, has been observed in NOTCH3-containing CADASIL protein aggregates [137], arguing that the protein aggregates in CADASIL may serve as a molecular sink for HTRA1. Interestingly, the Htra1 gene is predominantly expressed by astrocytes in mice and may exert its normal function in the PVS implicated in sympathetic function [17]. CAA is classified as an SVD [133], but has, as discussed above, close bearings to AD (for review see [138]), which further underscores the similarities between neurodegenerative and vascular diseases. How the vascular damage in any of these diseases leads to WML is not well-understood, but an intriguing idea is that there is a direct relationship between cells in the vasculature and cells in the oligodendrocyte lineage, which produce myelinination in the white matter [134]. Expression of the chemokine ligand CXCL12 from the vasculature has been proposed to activate CXCR4 receptor signaling in oligodendrocyte progenitors [139], which may provide such a vasculature–white matter link. The notion of a vascular white matter cross-talk is supported by several additional reports. Notably, BDNF and FGF produced by endothelial cells promote survival and proliferation of oligodendrocyte progenitors [140], for review see ref. [141]. Similarly, OPC migrate along the vasculature during CNS development in response to endothelial cell-derived CXCL12, which acts on CXCR4 on the oligodendrocyte progenitors [142]. Direct interactions between pericytes and oligodendrocyte progenitors [143], as well as a role for pericytes in oligodendrocyte differentiation [144], have also been proposed, and a putative perivascular source of oligodendrocyte progenitors has been identified that can be activated following oligodendrocyte progenitor ablation [145]. To what extent these mechanisms are altered in SVD will be an interesting avenue for future research.

Which additional molecular mechanisms may get detailed in the brain vasculature in SVD? PDGF signaling is, as discussed above, a key signaling mechanism in pericytes but there are also other signaling mechanisms important for the BBB and pericytes, including angiopoietin-1/Tie-2 and TGFβ signaling [18]. A link between PDGF and TGFβ signaling has recently been presented, where TGFβ expression after experimental stroke was reduced in mice with compromised PDGF signaling [146]. Furthermore, as discussed above, ALK5 signaling in pericytes upregulates TIMP3 expression, leading to enhanced metalloproteinase activity [33]. Enhanced activation of matrix metalloproteinases at pericyte somata has also been reported in response to experimental occlusion of cortical capillaries [147]. An interesting risk factor for SVD is mutations in the transcription factor FOXF2, which is expressed in pericytes and endothelial cells [148]. In line with this, deletion of Foxf2 in the mouse affects pericyte differentiation and BBB integrity [149].

Pericytes are, in addition to controlling BBB integrity, likely involved in the aftermath of an ischemic stroke, in which the blood flow to the brain is suddenly disrupted by a post-stroke CBF reduction in the microvessels. This capillary constriction exacerbates the ischemia, and damage to the brain and pericytes have been implicated in the post-stroke CBF regulation and capillary constriction. It was proposed that pericytes constrict capillaries after reduction in ATP levels (chemical ischemia) [40] and die after capillary constriction, presumably in a constricted state [40,150]. Mechanistically, ischemia-induced pericyte constriction can be relieved by suppressing oxidative-nitrative stress [52]. Furthermore, in the heart, capillary blockage following coronary artery occlusion colocalized with pericytes, and treatment with adenosine, which relaxes pericytes, increased perfusion, corroborating a role for pericytes in the post-stroke blood flow reduction [151]. Considering some current controversies and, seemingly, contradictions in the published data, it is important to remember that the mentioned studies define mural cells as pericytes rather than VSMC based on the diameter of the vessels they surround. This contrasts with our recently published molecular definition of pericytes and discrimination between pericytes and VSMC that are based on single-cell RNA-sequencing [17]. Importantly, these different definitions of where the exact anatomical “border” should be drawn between an arteriole and a capillary is directly related to the controversy about whether brain pericytes are α-SMA-positive or not [51]. By applying the same criteria for mural cell classification as we did in our single-cell study, Hill et al [44] concluded that arteriolar SMC—not pericytes—are responsible for the microvessel constriction following brain ischemia. While the controversies about mural cell contractility after stroke might boil down to different nomenclature, rather than conflicting data, further research is required to precisely define the role of the various mural cell types in post-stroke capillary constriction.

In addition, pericytes have been proposed to shift their cellular phenotype toward microglia [152] or cause an accumulation of ECM following stroke [150]. Pericyte loss has also been observed in premature infants [153], and it will be interesting to learn how this relates to the effects on brain function that in some cases are observed later in life after premature births. Pericytes have been implicated in scar formation in the brain following cerebral ischemia. Proliferation of PDGFRβ and CD105-positive stromal cells, which may be derived from a sub-population of pericytes, was observed following experimental ischemia in mice, and these cells would deposit ECM leading to post-ischemic scarring [150]. The stromal cells have a similar marker profile as cells involved in scar formation in the spinal cord, which also are proposed to be pericyte-derived [154,155]. While these cells share several markers with pericytes, it has, however, been proposed that the cells involved in the scar process instead are perivascular fibroblasts [156]. The molecular characterization of pericytes and perivascular brain fibroblasts in the mouse brain may support the latter notion [17], but more research is required to establish the precise nature of the cells involved in scar formation in the brain and spinal cord.

Enlarged PVS are a hallmark of and diagnostic criterion for SVD [157], but the reason why PVS are enlarged in SVD and a number of other brain diseases is poorly understood. It may be that the enlargement causes impaired paravascular flow, leading to reduced clearance, or conversely that accumulation of Aβ and other aggregates leads to the observed expansion of the PVS (for review see ref. [57]). Alternatively, PVS enlargement may be caused by inflammation, for example, in multiple sclerosis [158], and in line with this idea, inflammatory cells are indeed observed in the PVS [57]. Recent data reveal a genetic component for PVS enlargement, at least in certain regions of the brain (the basal ganglia) [159], and this genetic link could be a starting point for a search for genes implicated in PVS organization and function. The recent characterization of perivascular brain fibroblasts that are located along the PVS [17] (see above) may contribute to a better understanding of the cellular...
architecture of the PVS. The function of these cells is not yet well-understood, but it is notable that they express transporters as well as specific ECM components, indicating that they may play a role in regulating paravascular flow. While these cells thus far have only been analyzed in detail in the mouse, it is, as discussed above, reasonable to assume that they also exist in the human brain, based on histological analysis of human brain blood vessels, which identifies cells with a similar localization around blood vessels [78]. The identification of genes uniquely expressed in the perivascular brain fibroblasts may stimulate identification of novel biomarkers that can be used for analysis of the human brain, both for histological analysis of post-mortem brain tissue and for possible generation of new positron-emission tomography (PET) ligands in the long term, which may be useful to more precisely analyze PVS enlargement in patients with SVD and other neurological disorders.

Unraveling specific links between the vasculature and the CNS in genetic mouse models

As discussed above, loss or impairment of cell types in the CNS affects the vasculature, and conversely, vascular problems lead to a dysfunctional CNS. While there are obvious large-scale neuronal and white matter changes as a result of stroke, there are, however, also effects in the CNS resulting from more subtle modulations of the vasculature. Identifying molecular mechanisms operating in the CNS–vascular communication and which “relay” injury information from the neural to the vascular part, and vice versa, is important. Cell type-specific modulation of genes in genetic mouse models is increasingly used to address these issues. This field is still at an early stage, but progress in genome-editing techniques combined with improved opportunities for tissue-specific expression of CRE recombinase and specific genes facilitates advancement in making more precise mouse models, and below we provide some examples of progress in the area of genetically modified mice.

The NVU is an important node for CBF control and constitutes a physical interface between cells from the CNS and the vasculature (Fig 2). As such, it provides a potentially interesting node for CNS–vascular communication, and it is an emerging notion that neurons and astrocytes exert important control functions over pericytes and endothelial cells in the BBB. ATP and adenosine from neurons act on adenosine receptors on the vascular cells, and arachidonic acid derivatives (including 20-HETE, see below) from astrocytes also influence the vascular cells. Expression of human apolipoprotein E (APOE) in astrocytes in the mouse (driven from the GFAP promoter) resulted in an increase in CypA expression in pericytes and loss of BBB integrity [160]. In line with this, pericyte loss is accelerated in humans carrying the APOE4 allele [88]. In a recent study, expression of tau in neurons of mice (the Tg4510 mouse model) resulted in an increased cortical microvasculature, with elevated numbers of small-diameter blood vessels [161].

Conversely, experimental manipulation of gene functions in vascular cells in the mouse affects the CNS. Removal of Glut1 from the mouse endothelium causes BBB breakdown, accompanied by a worsened neuropathology and decline in cognitive function [162]. In line with this, genetic GLUT1 defects in humans give rise to infantile seizures, microcephaly, and ataxia, underscoring the importance of a functional BBB (see ref. [163] for review). Interestingly, repletion of Glut1 (by viral transduction) in Glut1-deficient mice averts some of the microvascular defects [164]. Gene perturbations specifically affecting pericytes and VSMC may be useful tools to study the impact of a primary vascular injury on the CNS. Pericyte deficiency (using the PdgfrbF7/7 mouse, see above) leads to white matter degeneration, changes in oligodendrocyte number, and dilatation of PVS at a time window where pericytes but not VSMC are affected [165]. Furthermore, loss of pericytes reduces clearance of Aβ in a mouse model overexpressing APP [87], and pericyte-deficient mice show signs of neurodegeneration and cognitive decline [38]. Expression of a CADASIL-mutated form of the Notch3 gene in VSMC in the mouse results in white matter lesions, similar to those observed in CADASIL patients [166]. In conclusion, these observations support the notion that specific genetic perturbations in the CNS or vascular system can affect other tissues and lend support to the fact that precise mouse models are important tools to investigate CNS–vascular communication mechanisms.

Toward therapy development

Development of therapeutic strategies that can restore a damaged vasculature and BBB is a prioritized goal not only for cerebrovascular diseases but will likely also become a component of future neurodegenerative disease treatment. BBB leakage may occur through disturbed transcytosis or breakage of the junctions between endothelial cells, leading to paracellular leakage. In the first category, a recent report suggests that reduced N-cadherin expression in pericytes increases transendothelial transport [167]. The pericyte represents a cell type of particular therapeutic interest, given its critical role in controlling BBB integrity via regulation of endothelial barrier function. Interestingly, imatinib (Gleevec) has been shown to improve BBB integrity caused by pericyte deficiency [20], and cilostazol/iloprost reduces pericyte detachment in an experimental stroke model in rat [168]. Pericytes exhibit plasticity after experimental injury [169], supporting the notion that their function may be improved or restored in an injury situation. The study of BBB integrity in in vitro systems could clearly accelerate research and allow high-throughput screens to be conducted (for review see ref. [170]). Although not perfect mimics of the in vivo situation, organoid-based in vitro BBB systems for endothelium–pericyte interactions have recently been developed [171,172]. Such three-dimensional tissue-mimicking systems may be better approximations of the in vivo situation than their two-dimensional counterparts, and it will be interesting to learn whether these systems will accelerate the discovery of therapeutic agents and provide new insights into mechanisms affecting BBB integrity. A complementary, although less high-throughput, model system for drug screening is zebrafish, where the combination of transparent embryogenesis and new fluorescent reporters to identify the various vascular cell types allows BBB function and other aspects of vascular biology to be monitored in vivo [173] (for review see ref. [174]).

Therapies improving the outcome after ischemic stroke are also warranted but altered BBB permeability is a critical issue. Directly after acute ischemic stroke, tissue plasminogen activator (tPA) is used for thrombolysis, but beyond a few hours-long time window of therapeutic opportunity, tPA treatment is associated with intracerebral hemorrhage, a consequence of induced BBB breakdown.
Recently, it has been demonstrated that PDGF signaling (PDGF-CC/PRGFRα) may become induced downstream of tPA as a consequence of tPA-mediated cleavage and activation of latent PDGF-CC, and that modulation of PDGF may improve post-stroke BBB function [175]. The mechanism of PRGFRα–induced BBB disruption is not understood, but intriguingly, the expression of Pdgfra is largely restricted to perivascular fibroblasts among the different cell types of the NVU [17]. Along similar lines, the tyrosine kinase inhibitor imatinib, an efficient inhibitor of PDGFR signaling, was reported to reduce neurological disability after ischemic stroke [176]. As discussed above, pericytes are important for the constriction of capillaries and reduced CBF observed in the post-stroke situation [39,40]. 20-HETE has been shown to constrict pericytes [40], and thus represents an interesting potential therapeutic target. As pericyte contractility is controlled by intracellular Ca2+ levels, modulation of the Ca2+ levels represents another interesting therapeutic possibility, although the overall efficacy of this approach still remains to be proven. An alternative approach is based on focused ultrasound, which may transiently open BBB to release toxic Aβ from AD patients [177].

While restoration of the BBB is the goal in disease situations characterized by an aberrant and leaky BBB, there are also situations where transiently enhanced BBB permeability could be advantageous. The barrier function of the BBB currently poses a problem for many therapeutic agents to effectively be transported from the blood to the brain, for example, in the treatment of brain tumors such as glioblastoma. Novel strategies to selectively enhance BBB permeability, possibly by transiently inhibiting pericyte function, can be considered. Approaches enhancing transcytosis have been attempted in the area of immunization-based AD therapies, for example, by using transferrin receptor-mediated transcytosis of anti-Aβ antibodies using a bivalent antibody strategy [178,179], and may be considered also to modulate pericyte function. To enhance paracellulart transport by transiently disrupting the tight junction complexes is an alternative strategy, and in mice with cerebral edema, reduced swelling and cognitive improvement were observed upon siRNA knockdown of Cldn5 [180]. The beneficial effect of Cldn5 knockdown may seem paradoxical given that full knockout of the gene in mice is lethal [36]; however, a complete breakdown of endothelial junctions is not observed in these mice [36]. Cldn5 modulation may therefore be an interesting therapeutic avenue to resolve brain edema or allow transient passage of drugs. However, despite its fundamental importance for the BBB, the Cldn5 and tight junction dynamics at the BBB are still poorly understood, and the possibility of exploiting this molecule for therapeutic purposes requires further study.

Concluding remarks

Neurodegenerative and cerebrovascular diseases have major medical, social, and economic consequences. Although progress is made in identifying pathomechanisms for these disease categories, it is an emerging notion that there are several links between neurodegenerative and cerebrovascular diseases, and to understand these links may provide new angles for therapy development and for a more complete understanding of the disease process. A central cell type at the interface between the CNS and vasculature is the pericyte, which is a universal component of the microvasculature, but nevertheless seems to play specific roles for the BBB. Investigation into the organ-specific specialization of pericytes is still at its infancy, but data collected thus far point to the presence of specific functions for brain pericytes [17]. Changes in pericyte function may have immediate consequences for CBF and BBB function, and therefore, to deconvolute how vascular dysfunction may cause, for example, white matter lesions will be important topics for future study. There are additional outstanding questions in this area, including whether there are qualitative differences in the microvasculature in different brain areas and whether pericyte–endothelial interactions differ, for example, between gray and white matter. While the available data do not indicate extensive brain pericyte heterogeneity at the transcriptomic level, more focused, brain region-specific analyses need to be undertaken. With increasing knowledge about molecular mechanisms operating in pericytes, and in the contact between pericytes and other cell types, new possibilities to control pericyte function may be envisaged. There are situations where pericyte function would need to be restored, but also situations where a transiently induced pericyte dysfunction could be beneficial, for example, to increase access to the brain for drug delivery or to decrease brain edema. With recent insights into the transcriptional nature of pericytes and other vascular cell types in the brain, research in these areas may be further accelerated, and it will be interesting to witness the developments over the next few years.

Acknowledgements

The work carried out in the authors’ laboratories was supported by the Swedish Research Council, Hjämfonden (UL), Hållstens Forskningsstiftelse, Alzheimerfonden (PN), Knut and Alice Wallenberg Foundation, the Swedish...
Cancer Foundation, The Leducq Foundation, and the Louis-Jeantet Foundation (CB).

Conflict of interest

The authors declare that they have no conflict of interest.

References

1. Saunders A, Macosko EZ, Wysoker A, Goldman M, Krienen FM, de Rivera H, Bien E, Baum M, Bortolin L, Wang S et al (2018) Molecular diversity and specializations among the cells of the adult mouse brain. Cell 174: 1015–1030
2. Zeisel A, Hochgener H, Lönnerberg P, Johnson A, Memic F, van der Zwan J, Häring M, Braun E, Born L, La Manno G et al (2018) Molecular architecture of the mouse nervous system. Cell 174: 999 – 1014
3. Muñoz-Manchado AB, Bengtsson Gonzales C, Zeisel A, Munguba H, Bekkouche B, Skene NG, Lönnerberg P, Ryge J, Harris KD, Linnarsson S et al (2018) Diversity of interneurons in the dorsal striatum revealed by single-cell RNA sequencing and PatchSeq. Cell Rep 24: 2179–2190.e7
4. Harris KD, Hochgener H, Skene NG, Magnlo L, Katona L, Bengtsson Gonzales C, Somogyi P, Kessaris N, Linnarsson S, Hjerling-Leffler J (2018) Classes and continua of hippocampal CA1 inhibitory neurons revealed by single-cell transcriptomics. PLoS Biol 16: 1 – 37
5. Häring M, Zeisel A, Hochgener H, Runwa P, Jakobsson JET, Lönnerberg P, La Manno G, Juréus A, Marques S, Munguba H, He L, Betsholtz C et al (2015) Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 347: 1138 – 1142
6. Zeisel A, Munoz-manchado AG, Codeluppi S, Lönnerberg P, La Manno G, Juréus A, Marques S, Munguba H, He L, Betsholtz C et al (2015) Cell types in the mouse cortex and hippocampus revealed by single-cell transcriptomics. PLoS Biol 13: e1002218
7. Marques S, Zeisel A, Codeluppi S, Van Bruggen D, Falcão AM, Xiao L, Li H, Häring M, Hochgener H, Romanov RA et al (2016) Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science 352: 1326 – 1329
8. Marques S, van Bruggen D, Vanlandewijck M, Lebouvier T, Mäe MA, Nahar K, Hornemann S, Kenkel D, Cunha SI, Lennartsson J, Boss A, Heldin CH et al (2018) Transcriptional convergence of oligodendrocyte lineage progenitors during development. Deu Cell 46: 504 – 517.e7
9. Hochgener H, Zeisel A, Lönnerberg P, Linnarsson S (2018) Conserved properties of dentate gyrus neurogenesis across postnatal development revealed by single-cell RNA sequencing. Nat Neurosci 21: 290 – 299
10. La Manno G, Gyllborg D, Codeluppi S, Nishimura K, Salto C, Zeisel A, Born LE, Stott SRW, Toledo EM, Villascsua JC et al (2016) Molecular diversity of midbrain development in mouse, human, and stem cells. Cell 167: 566 – 580.e19
11. Mathys H, Davila-Velderrain J, Peng Z, Gao F, Momhammad S, Young JZ, Menon M, He L, Abdurrob F, Jiang X et al (2019) Single-cell transcriptional analysis of Alzheimer's disease. Nature 570: 332 – 337
12. Falcão AM, van Bruggen D, Marques S, Meijer M, Jakel S, Agirre E, Samudypata EM, Vanichkina DP, Ffrench-Constant C, Williams A et al (2018) Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat Med 24: 1837 – 1844
13. Caruso RA, Fedele F, Finocchiaro G, Pizzi G, Nunnari M, Gitto G, Fabiano V, Parisi A, Venuti A (2009) Ultrastructural descriptions of pericyte/endothelium peg-socket interdigitations in the microvascularity of human gastric carcinomas. Anticancer Res 29: 449 – 453
14. Bigler M, Koustantonis D, Odrozola A, Halm S, Tschanz SA, Zakrzewicz A, Weichert A, Baum O (2016) Morphometry of skeletal muscle capillaries: the relationship between capillary ultrastructure and ageing in humans. Acta Physiol 218: 98 – 111
15. Waters JP, Kluger MS, Graham M, Chang WG, Bradley JR, Pober JS (2013) In vitro self-assembly of human pericyte-supported endothelial microvessels in three-dimensional coculture: a simple model for interrogating endothelial-pericyte interactions. J Vasc Res 50: 324 – 331
16. Diaz-Flores L, Gutierrez R, Varela H, Rancel N, Valladares F (1991) Microvascular pericytes: a review of their morphological and functional characteristics. Histol Histopathol 6: 269 – 286
17. Vanlandewijck M, He L, Mæa MA, Andrae J, Ando K, Del Gaudio F, Nahar K, Lebouvier T, Lavila B, Gouveia L et al (2018) A molecular atlas of cell types and zonation in the brain vasculature. Nature 554: 475 – 480
18. Armulik A, Genové G, Betsholtz C (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 21: 193 – 215
19. Mathisen TM, Lehre KP, Danbolt NC, Ottersen OP (2010) The perivascular astroglial sheath provides a complete covering of the brain microvesels: an electron microscopic 3D reconstruction. Glia 58: 1094 – 1103
20. Armulik A, Genové G, Mæa M, Nisancioglu MH, Wallgard E, Ninanet C, He L, Norlin J, Lindblom P, Strittmatter K et al (2010) Pericytes regulate the blood-brain barrier. Nature 468: 557 – 561
21. Daneman R, Zhou L, Kebede AA, Barres BA (2010) Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 468: 562 – 566
22. Ostman A, Andersson M, Betsholtz C, Westermark B, Heldin CH (1991) Identification of a cell retention signal in the B-chain of platelet-derived growth factor and in the long splice version of the A-chain. Cell Regul 2: 503 – 512
23. Vanlandewijck M, Lebouvier T, Mæa MA, Nahar K, Homemann S, Kenkel D, Cunha SI, Lennartsson J, Boss A, Heldin CH et al (2015) Functional characterization of germline mutations in PDGFB and PDGFRB in primary familial brain calcification. PLoS ONE 10: 1 – 25
24. Villaseñor R, Kuennecke B, Ozmen L, Ammann M, Kugler C, Grüninger F, Loetscher H, Freskgård PO, Collin L (2017) Region-specific permeability of the blood-brain barrier upon pericyte loss. J Cereb Blood Flow Metab 37: 3683 – 3694
25. Tallquist MD, French WJ, Soriano P (2003) Additive effects of PDGF receptor β signaling pathways in vascular smooth muscle cell development. PLoS Biol 1: 288 – 299
26. Nikofskoupolou AM, Zhao Z, Montagne A, Zlokovic BV (2017) Regional early and progressive loss of brain pericytes but not vascular smooth muscle cells in adult mice with disrupted platelet-derived growth factor receptor-β signaling. PLoS ONE 12: 1 – 19
27. Jin S, Hansson EM, Tikka S, Lanner F, Sahlinen C, Farnebo F, Baumann M, Kalimo H, Lendahl U (2008) Notch signaling regulates platelet-derived growth factor receptor-β expression in vascular smooth muscle cells. Circ Res 102: 1483 – 1491
28. Domenga R, Fardoux P, Lacombe P, Monet M, Maciazek J, Krebs LT, Konjokowskia B, Berrou E, Mercickay M, Li Z et al (2004) Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 18: 2730 – 2735
29. Wang Y, Pan L, Moens CB, Appel B (2014) Notch3 establishes brain vascular integrity by regulating pericyte number. Development 141: 307 – 317
1. Chen J, Luo Y, Hui H, Cai T, Huang H, Yang F, Feng J, Zhang J, Yan X (2017) CD146 coordinates brain endothelial cell-pericyte communication for blood-brain barrier development. Proc Natl Acad Sci USA 114: E7622–E7631.

2. Lindahl P, Johansson BR, Levén P, Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice per lindahl. Science 277: 242–245.

3. Dubrac A, KüNZel SE, KüNZel SH, Li J, Chandran RR, Martin K, Greif DM, Adams RH, Eichmann A (2018) NCX-dependent pericyte migration promotes pathological neovascularization in ischemic retinopathy. Nat Commun 9: 1–15.

4. Dave JM, Mirabella T, Weatherbee SD, Greif DM (2018) Pericyte ALKS/TIMP3 axis contributes to endothelial morphogenesis in the developing brain. Dev Cell 44: 193–215.

5. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126: 3047–3055.

6. Villaseñor R, Schilling M, Sundaresan J, Lutz Y, Collin L (2017) Sorting tubes regulate blood-brain barrier transcytosis. Cell Rep 21: 3256–3270.

7. Nitta T, Hata M, Gotoh S, Sato S, Hashimoto N, Furuse M, Tsukita S (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161: 633–660.

8. Greene C, Campbell M (2016) Tight junction modulation of the blood brain barrier: CNS delivery of small molecules. Tissue Barriers 4: e1138017.

9. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68: 409–427.

10. Peppiatt CM, Howarth C, Mobbs P, Attwell D (2006) Bidirectional control of CNS capillary diameter by pericytes. Nature 443: 700–704.

11. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, Oğü Farrell FM, Buchan AM, Lauritzen M, Attwell D (2014) Capillary pericytes regulate cerebral blood flow in health and disease. Nature 508: 55–60.

12. Kisler K, Nelson AR, Rege SV, Ramanathan A, Wang Y, Ahuja A, Lazic D, Tsai PS, Zhao Z, Zhou Y et al (2017) Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain. Nat Neurosci 20: 406–416.

13. Kisler K, Nelson AR, Montagne A, Zlokovic BV (2017) Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci 18: 419–434.

14. Mishra A, Reynolds JP, Chen Y, Bourine AV, Rusakov DA, Attwell D (2016) Astrocytes mediate neurovascular signaling to capillary pericytes but not to arteries. Nat Neurosci 19: 1619–1627.

15. Hill RA, Tong L, Yuan P, Murikinati S, Gupta S, Grutzendler J (2015) Regional blood flow in the normal and ischemic brain is controlled by arteriolar smooth muscle cell contractility and not by capillary pericytes. Neuron 87: 95–110.

16. Wei HS, Kang H, Rasheed IYD, Zhou S, Lou N, Gershtein A, McConnell ED, Wang Y, Richardson KE, Palmer AF et al (2016) Erythrocytes are oxygen-sensing regulators of the cerebral microcirculation. Neuron 91: 851–862.

17. Daneman R, Zhou L, Agalliu D, Cahoy JD, Kaushal A, Barres BA (2010) The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS ONE 5: e13741.

18. Henshall TL, Keller A, He L, Johansson BR, Wallgard E, Raschperger E, Moe MA, Jin S, Betsholtz C, Lindahl U (2014) Notch3 is necessary for blood vessel integrity in the central nervous system. Arterioscler Thromb Vasc Biol 35: 409–420.

19. He L, Vanlandewijck M, Raschperger E, Andaloussi Mæe M, Jung B, Lebouvier T, Ando K, Hofmann J, Keller A, Betsholtz C (2016) Analysis of the brain mural cell transcriptome. Sci Rep 6: 1–13.

20. Holm A, Heumann T, Augustin HG (2018) Microvascular mural cell organotypic heterogeneity and functional plasticity. Trends Cell Biol 28: 302–316.

21. Damisah EC, Hill RA, Tong L, Murray KN, Grutzendler J (2017) A fluorescent Nissl dye identifies pericytes as distinct vascular mural cells during in vivo brain imaging. Nat Neurosci 20: 1023–1032.

22. Attwell D, Mishra A, Hall CN, Farrell FM, Dalkara T (2016) What is a pericyte? J Cereb Blood Flow Metab 36: 451–455.

23. Yeum S, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K, Dalkara T (2009) Pericyte contraction induced by oxidative-nitrative stress impairs capillary refill following successful opening of an occluded cerebral artery. Nat Med 15: 1031–1037.

24. Bandopadhayay R, Orte C, Lawrenson JG, Reid AR, De Silvea S, Altg U (2001) Contractile proteins in pericytes at the blood-brain and blood-retinal barriers. J Neurocytol 30: 35–44.

25. Alarcon-Martinez L, Yilmaz-Ozcan S, Yeum S, Schallek J, Kilic K, Can A, Di Polo A, Dalkara T (2018) Capillary pericytes express α-smooth muscle actin, which requires prevention of filamentous-actin depolymerization for detection. Elife 7: 1–17.

26. Da Mesquita S, Louveau A, Vaccari A, Sminov I, Cornelison RC, Kingsmore KM, Contarino C, Onengut-gumuscu S, Farber E, Raper D et al (2018) Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease. Nature 560: 185–191.

27. Abbott NJ, Pizzo ME, Preston JE, Janigro D, Thorne RG (2018) The role of brain barriers in fluid movement in the CNS: is there a ‘glymphatic’ system? Acta Neuropathol 135: 387–407.

28. Brown R, Benveniste H, Black SE, Charpak S, Dighmans M, Joutel A, Nedergaard M, Smith KJ, Zlokovic BV, Wardlaw JM (2018) Understanding the role of the perivascular space in cerebral small vessel disease. Cardiovasc Res 114: 1462–1473.

29. Morris AWJ, Sharp MMC, Albargothy NJ, Fernandes R, Hawkes CA, Verma A, Weller RO, Carare RO (2016) Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol 131: 725–736.

30. Patel TK, Habimana-Griffin L, Gao X, Xu B, Achilefu S, Alitalo K, McKee CA, Sheenan PW, Usiek ES, Xiong C et al (2019) Dural lymphatics regulate clearance of extracellular tau from the CNS. Mol Neurodegener 14: 11.

31. Plog BA, Nedergaard M (2018) The glymphatic system in central nervous system health and disease: past, present, and future. Annu Rev Pathol 13: 379–394.

32. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiagarajan M, Donnell JO, Sheenan PW, Usiek ES, Xiong C et al (2019) Sleep drives metabolite clearance from the adult brain. Science 342: 373–377.

33. Munk AS, Wang W, Bechet NB, Eltanahy AM, Cheng AX, Sigurdsson B, Benraiss A, Mæe MA, Kress BT, Kelley DH et al (2019) PDGF-B is required for development of the glymphatic system. Cell Rep 26: 2955–2969.e3.

34. Mestre H, Habislit LM, Xavier ALR, Feng W, Zou W, Pu T, Monai H, Muridihanar G, Rivera RMC, Simon MJ et al (2018) Aquaporin-4-dependent glymphatic solute transport in the rodent brain. Elife 7: e40070.
64. Smith AJ, Yao X, Dix JA, Jin B-J, Verkman AS (2017) Test of the 'glymphatic' hypothesis demonstrates diffuse and aquaporin-4-independent solute transport in rodent brain parenchyma. *Elife* 6: 1–16

65. Holter KE, Kehlet B, Devor A, Sejnowski TJ, Dale AM, Omholt SW, Ottersen OP, Nagelhus EA, Mardal K-A, Pettersen KH (2017) Intestinal solute transport in 3D reconstructed neuropil occurs by diffusion rather than bulk flow. *Proc Natl Acad Sci* 114: 9894–9899

66. Asgari N, Berg CT, March MT, Khoroooshi R, Owens T (2015) Cerebrospinal fluid aquaporin-4-immunoglobulin G disrupts blood brain barrier. *Ann Clin Transl Neurol* 2: 857–863

67. Asgari M, De Zélicourt D, Kurtcuoglu V (2016) Glymphatic solute transport does not require bulk flow. *Sci Rep* 6: 1–11

68. Jin B-J, Smith AJ, Verkman AS (2016) Spatial model of convective solute transport in brain extracellular space does not support a "glymphatic" mechanism. *J Gen Physiol* 148: 489–501

69. Spector R, Robert Snodgrass S, Johanson CE (2015) A balanced view of the cerebrospinal fluid composition and functions: focus on adult humans. *Exp Neurol* 273: 57–68

70. Albargothy NJ, Johnston DA, MacGregor-Sharp M, Weller RO, Verma A, Hawkes CA, Carare RO (2018) Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate perivascular basement membrane pathways. *Acta Neuroopathol* 136: 139–152

71. Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling J, Fuller PM et al (2019) The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. *Science* 884: 880–884

72. Deane R, Wu Z, Sagare A, Davis J, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X et al (2004) LRP/Amyloid b-peptide interaction mediates differential brain efflux of Ab isoforms. *Neuron* 43: 333–344

73. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV (2008) apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. *J Clin Invest* 118: 4002–4013

74. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Firemans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV et al (2015) Clear-ance systems in the brain – implications for Alzheimer disease. *Nat Rev Neurol* 11: 457–470

75. Cuadagno E, Moukhles H (2004) Laminin-induced aggregation of the inwardly rectifying potassium channel, Kir4.1, and the water-permeable channel, AQP4, via a dystroglycan-containing complex in astrocytes. *Glia* 47: 138–149

76. Menezes MJ, McLeanahan FK, Leiton XCV, Mardal K-A, Pettersen KH (2014) The extracellular matrix protein laminin a2 regulates the maturation and function of the blood – brain barrier. *J Neurosci* 34: 15260–15280

77. Hannock MJ, Pizzo ME, Huppert CT, Abbott N, Thorne RG, Sorokin L (2018) Molecular characterization of perivascular drainage pathways in the murine brain. *J Cereb Blood Flow Metab* 38: 669–686

78. Zhang ET, Inmant CBE, Weller R (1990) Intereationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cere- brum. *J Anot* 170: 111–123

79. Yu J-T, Tan L, Hardy J (2014) Apolipoprotein E in Alzheimer’s disease: an update. *Ann Rev Neurosci* 37: 79–100

80. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD (1999) Cerebrovas- cular disease and threshold for dementia in the early stages of Alzhei-mer’s disease. *Lancet* 354: 919–920

81. Casserly I, Topol E (2004) Convergence of atherosclerosis and Alzhei-mer’s disease: inflammation, cholesterol, and misfolded proteins. *Lancet* 363: 1139–1146

82. Henstridge CM, Hyman BT, Spires-Jones TL (2019) Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis. *Nat Rev Neurosci* 20: 94–108

83. Sweeney MD, Kisler K, Montagne A, Toga AW, Zlokovic BV (2018) The role of brain vasculature in neurodegenerative disorders. *Nat Neurosci* 21: 1318–1331

84. Farkas E, Luiten PGM (2001) Cerebral microvascular pathology in aging and Alzheimer’s disease. *Prog Neurobiol* 64: 575–611

85. Baloyannis SJ, Baloyannis IS (2012) The vascular factor in Alzheimer’s disease: a study in Golgi technique and electron microscopy. *J Neurol Sci* 322: 117–121

86. Sengillo JD, Winkler EA, Walker CT, Sullivan JS, Johnson M, Zlokovic BV (2013) Deficiency in mural vascular cells coincides with blood-brain barrier disruption in alzheimer’s disease. *Brain Pathol* 23: 303–310

87. Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramathan A, Zlokovic BV (2013) Pericyte loss influences Alzheimer-like neurodegeneration in mice. *Nat Commun* 4: 1–14

88. Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, Zlokovic BV (2016) Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease. *J Cereb Blood Flow Metab* 36: 216–227

89. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs RE, Liu CY, Amezcue L et al (2015) Blood-Brain barrier breakdown in the aging human hippocampus. *Neuron* 85: 296–302

90. Nation D, Sweeney M, Montagne A, Sagare A, D’Orazio L, Pachicano M, Sepehrband F, Nelson A, Buenagel D, Harrington M et al (2019) Blood-brain barrier breakdown is an early biomarker of human cogni-tive dysfunction. *Nat Med* 25: 270–276

91. Jellinger KA (2010) Prevalence and impact of cerebrovascular lesions in Alzheimer and lewy body diseases. *Neurodegener Dis* 7: 112–115

92. Marchesi VT (2011) Alzheimer’s dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysreg-uulated amyloid metabolism: implications for early detection and ther-apy. *FASEB J* 25: 5–13

93. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ et al (2011) Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer’s disease: a population-based study. *Circulation* 123: 769–7206

94. Wolters FJ, Zonneveld HI, Hofman A, Van Der Lught A, Koudstaal PJ, Vernooij MW, Ikram MA (2017) Cerebral perfusion and the risk of dementia: a population-based study. *Circulation* 136: 719–728

95. Leijenaar RF, van Maurik IS, Henstridge CM, Hyman BT, Spires-Jones TL, van der Flier WM, Scheltens P, Weiner MW, Aisen P, Petersen R, Jack CR et al (2016) Lower cerebral blood flow in subjects with Alzheimer’s dementia, mild cognitive impairment, and subjective cogni-tive decline using two-dimensional phase-contrast magnetic resonance imaging. *Alzheimers Dement (Amst)* 9: 76–83

96. Aslani I, Habeck C, Scarmeas N, Borogovac A, Brown TR, Stern Y (2008) Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer’s disease. *J Cereb Blood Flow Metab* 28: 725–736

97. Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC, Weiner MW, Aisen P, Petersen R, Jack CR, Jagust W et al. (2016) Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. *Nat Commun* 7: 11934

98. Hashimura T, Kimura T, Miyakawa T (1993) Morphological changes of blood vessels in the brain with Alzheimer’s disease. *Jpn J Psychiatry Neurol* 45: 661–665
99. Kimura T, Hashimura T, Miyakawa T (1991) Observations of microves- sels in the brain with Alzheimer’s disease by the scanning electron microscopy. Jpn J Psychiatry Neurosci 45: 671–676
100. Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s Dementia (N Y) 4: 575–590
101. Rensink AA, Veerbeek MM, Otte-Höller I, ten Donkelaar HT, de Waal RM, Kremer B (2002) Inhibition of amyloid-beta-induced cell death in human brain pericytes in vitro. Brain Res 952: 111–121
102. Buinsma IB, Wilhelmus MM, Kox M, Veurhis M, de Waal RM, Veerbeek MM (2010) Apolipoprotein E protects cultured pericytes and astrocytes from D-Aβ1-40-mediated cell death. Brain Res 1315: 169–180
103. Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV (2018) Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isofrom-specific mechanism. Mol Neurode- gener 13: 1–13
104. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, Carlson GA, Iadecola C (2000) Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A 97: 9735–9740
105. Thal DR, Griffin WS, de Vos RA, Ghebremedhin E (2008) Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease. Acta Neuropathol 115: 599–609
106. Hecht M, Kramer LM, von Armin CA, Otto M, Thal DR (2018) Capillary cerebral amyloid angiopathy in Alzheimer’s disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathol 135: 681–694
107. Hunter S, Brayne C (2018) Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease. Mol Psychiatry 23: 81–93
108. Li H, Guo Q, Inoue T, Polito VA, Tabuchi K, Hammer RE, Pautler RG, Taffet GE, Zheng H (2014) Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. Mol Neurodegener 9: 28
109. Wilcock DM, Vitek MP, Colton CA (2009) Vascular amyloid alters asto- cytic water and potassium channels in mouse models and humans with Alzheimer’s disease. Neuroscience 159: 1055–1069
110. Kelly P, Denner P, Satchell SC, Ackermann M, Konerding MA, Mitchell CA (2017) Microvascular ultrastructural changes precede cognitive impairment in the murine APPswe/PS1dE9 model of Alzheimer’s disease. Angiogenesis 20: 567–580
111. van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH (2017) Amyotrophic lateral sclerosis: Lancet 390: 2084–2098
112. Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Appel SH, Zlokovic BV (2013) Blood-spinal cord barrier breakdown and reorganization in amyotrophic lateral sclerosis. Acta Neuropathol 125: 111–120
113. Chondrogianni M, Bregianni M, Frantzeskaki F, Giamarres-Bourboulis E, Anagnostou E, Brakouzi E, Karadima G, Koutsis C, Moschosov C, Bonakis A et al (2018) Three new case reports of Arteriovenous malfor- mation-related Amyotrophic Lateral Sclerosis. J Neurol Sci 393: 58–62
114. Valavanis A, Schwarz U, Baumann CR, Wellner M, Linnebank M (2014) Amyotrophic lateral sclerosis after embolization of cerebral arteriove- nous malformations. J Neurol 261: 732–737
115. Abdellah A, Hübser A, Böhm K, Rudolph AC, Kassubek J, Pinkhardt EH (2018) In vivo assessment of retinal vessel pathology in amyotrophic lateral sclerosis. J Neurol 265: 949–953
116. Lewandowski SA, Nilsson I, Fredriksson L, Lönnberg P, Mušli L, Zeitel- hofer M, Adzemovic MZ, Nichtenwitz S, Lawrence DA, Hedin L, et al (2016) Presymptomatic activation of the PDGF–CC pathway accelerates onset of ALS neurodegeneration. Acta Neuropathol 131: 453–464
117. Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R et al (2018) Huntington disease. Nat Rev Dis Primers 1: 1–21
118. Padel T, Roth M, Gacek A, Li J-Y, Björkqvist M, Paul G (2018) Brain pericyte activation occurs early in Huntington’s disease. Exp Neurol 305: 139–150
119. Drouin-Ouellet J, Sawiak SJ, Cisbani G, Lagacé M, Kuan WL, Saint-Pierre M, Dury R, Alata W, St-Amour I, Mason SL et al (2015) Cerebrovascular and blood-brain barrier impairments in Huntington’s disease: potential implications for its pathophysiology. Ann Neurol 78: 160–177
120. Sicacca G, Cicchetti F (2017) Mutant huntingtin protein expression and blood-spinal cord barrier dysfunction in huntington disease. Ann Neurol 82: 981–994
121. Kealy J, Greene C, Campbell M (2018) Blood-brain barrier regulation in psychiatric disorders. Neurosci Lett https://doi.org/10.1016/j.neulet.2018.06.033 [Epub ahead of print]
122. Alves JL (2014) Blood-brain barrier and traumatic brain injury. J Neurosci Res 92: 141–147
123. Prakash R, Carmichael ST (2015) Blood-brain barrier breakdown and neurovascularization processes after stroke and traumatic brain injury. Curr Opin Neurol 28: 556–564
124. Dore-Duffy P, Owen C, Balabanov R, Murphy S, Beaumont T, Rafols JA (2000) Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res 60: 55–69
125. Zehndner CA, Sebastiani A, Hugonnet A, Bischoff F, Luhmann HJ, Thal SC (2015) Traumatic brain injury results in rapid pericyte loss followed by reactive pericytosis in the cerebral cortex. Sci Rep 5: 1–9
126. Iliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Singh I, Li, Nadee R, DePace M (2014) Impairment of glial fibrillary acidic protein pathway promotes tau pathology after traumatic brain injury. J Neurosci 34: 3647–3666
127. Farrell M, Ahern S, O’Riordan S, O’Keefe E, Greene C, Campbell M (2019) Blood-brain barrier dysfunction in a box with chronic traum- atic encephalopathy and schizophrenia. Clin Neuropathol 38: 51–58
128. Najjar S, Pearson DM, Alper K, Najjar A, Devinsky O (2013) Neuroinflam- mation and psychiatric illness. J Neuroinflammation 10: 43
129. Najjar S, Pahlajani S, De Sanctis V, Stern JNH, Najjar A, Chong D (2017) Neurovascular unit dysfunction and blood-brain barrier hyperperme- ability contribute to schizophrenia neurobiology: a theoretical integra- tion of clinical and experimental evidence. Front Psychiatry 8: 83
130. Hua J, Brandt AS, Lee S, Blair NIS, Wu Y, Li S, Patel J, Faria AV, Lim IAL, Unschuld PG et al (2017) Abnormal grey matter arteriolar cerebral blood volume in schizophrenia measured with 3D inflow-based vascu- lar-space-occupancy MRI at 7T. Schizophren Bull 43: 620–632
131. Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner HG (2017) Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 44: 321–330
132. Greene C, Kealy J, Humphries MM, Geng Y, Hou J, Hudson N, Cassidy LM, Martiniano R, Shashi V, Hooper S et al (2018) Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. Mol Psychiatry 23: 2156–2166
133. Pantoni L (2010) Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9: 689–701
134.  Mestre H, Kostrikov S, Mehta RI, Nedergaard M (2017) Perivascular spaces, lymphatic dysfunction, and small vessel disease. *Clin Sci* 131: 2257–2274

135.  Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cecilion M, Marechal E et al (1996) Notch3 mutations in Cadasil, a hereditary adult-onset condition causing stroke and dementia. *Nature* 383: 707 – 710

136.  Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, Yokoseki A, Kawata H, Koyama A, Arima K, Takahashi T et al (2009) Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. *N Engl J Med* 360: 1729-1739

137.  Zellner A, Scharrer E, Arzberger T, Oka C, Domenga-Denier V, Joutel A, Lichtenthaler SF, Müller SA, Díchos C, Hoffman C (2018) Cadasil brain vessels show a HTRA1 loss-of-function profile. *Acta Neuropathol* 136: 111 – 125

138.  Wermers MJH, Greenberg SM (2018) The growing clinical spectrum of cerebral amyloid angiopathy. *Curr Opin Neurol* 31: 28 – 35

139.  Joutel A, Chabriat H, Cottin V (2017) Pathogenesis of white matter changes in cerebral small vessel diseases: beyond vessel-intrinsic mechanisms. *Clin Sci* 131: 635–651

140.  Arii K, Lo EH (2009) An oligovascular niche: cerebral endothelial cells promote the survival and proliferation of oligodendrocyte precursor cells. *J Neurosci* 29: 4351–4355

141.  Hamanaka G, Ohtomo R, Takase H, Lok J, Arii K (2018) White-matter repair: interaction between oligodendrocytes and the neurovascular unit. *Brain Circ* 4: 118–123

142.  Tsai H-H, Niu J, Munji R, Davalos D, Chang J, Zhang H, Tien A-C, Kuo CJ, Chan JR, Daneman R et al (2016) Oligodendrocyte precursor migration along vasculature in the developing nervous system. *Science* 351: 379–384

143.  Maki T, Maeda M, Uemura M, Lo EK, Terasaki Y, Liang AC, Shindo A, Choi YK, Taguchi A, Matsuyama T et al (2015) Potential interactions between pericytes and oligodendrocyte precursor cells in perivascular regions of cerebral white matter. *Neurosci Lett* 597: 164–169

144.  De La Fuente AG, Lange S, Silva ME, Gonzalez GA, Tempfer H, van Wijngaarden P, Zhao C, Di Canio L, Troost A, Bieler L et al (2017) Pericytes stimulate oligodendrocyte progenitor cell differentiation during CNS remyelination. *Cell Rep* 20: 1755–1764

145.  Sheng Jiang TC, Ishii Y, De Nguyen V, Yamamoto S, Hamashima T, Okuno N, Nguyen QL, Sang Y, Ohkawa N, Saitoh Y et al (2019) Powerful homeostatic control of oligodendroglial lineage by PDGFαRα in adult brain. *Cell Rep* 27: 1073–1089.e5

146.  Shen J, Xu G, Zhu R, Yuan J, Ishii Y, Hamashima T, Matsushima T, Yamamoto S, Takatsuuri Y, Nabecky N, Cabelli R et al (2019) PDGFβ restores blood-brain barrier functions in a mouse model of focal cerebral ischemia. *J Cereb Blood Flow Metab* 39: 1501–1515

147.  Underly RG, Levy M, Hartmann DA, Grant RI, Watson AN, Shih AY (2017) Pericytes as inducers of rapid, matrix metalloproteinase-9-dependent capillary damage during ischemia. *J Neurosci* 37: 129–140

148.  Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium the SGN (Sgn) and the ISGC (ISGC) (2016) Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association. *Lancet Neurol* 15: 695–707

149.  Reijali A, Nik AM, Ghiani M, Giritli-Linde A, Pontén F, Johansson BR, Carlsson P (2015) Fox2 is required for brain pericyte differentiation and development and maintenance of the blood-brain barrier. *Dev Cell* 34: 19–32

150.  Fernández-Klett F, Potas JR, Hilpert D, Blazek J, Radke J, Huck J, Engel O, Stenzel W, Genové G, Priller J (2013) Early loss of pericytes and perivascular stromal cell-induced scar formation after stroke. *J Cereb Blood Flow Metab* 33: 428–439

151.  O’Farrell FM, Mastitskaya S, Hammond-Haley M, Freitas F, Wah WR, Attwell D (2017) Capillary pericytes mediate coronary no-reflow after myocardial ischaemia. *Elife* 6: 1–16

152.  Özen I, Dieierborg T, Mihara K, Patel T, Engelund E, Genové G, Paul G (2014) Brain pericytes acquire a microglial phenotype after stroke. *Acta Neuropathol* 128: 381 – 396

153.  Braun A, Xu H, Hu F, Kocherlakota P, Siegel D, Chander P, Ungvari Z, Csizsar A, Nedergaard M, Ballabh P (2007) Paucity of pericytes in germinat matrix vasculature of premature infants. *J Neurosci* 27: 12012–12024

154.  Göritz C, Dias DO, Tomlin N, Barbadic M, Shuplakov O, Frisen J (2011) A pericyte origin of spinal cord scar tissue. *Science* 333: 238–243

155.  Dias DO, Kim H, Holl D, Werner Solnestam B, Lundeberg J, Carlén M, Göritz C, Frisen J (2018) Reducing pericyte-derived scarbing promotes recovery after spinal cord injury. *Cell* 173: 153–165.e22

156.  Soderblom C, Luo X, Blumenthal E, Bray E, Lyapichev K, Ramos J, Krishnan V, Lai-Hsu C, Park K, Tsoulfas P et al (2013) Perivascular fibroblasts form the fibrotic scar after contusive spinal cord injury. *J Neurosci* 33: 13882–13887

157.  Wardlaw JM, Smith C, Díchos C (2013) Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. *Lancet Neurol* 12: 483–497

158.  Lassmann H (2019) Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. *Front Immunol* 9: 1–14

159.  Dupéron MG, Tzourio C, Sargurupremraj M, Mazoyer B, Soumaré A, Schilling S, Amouyel P, Chauhan G, Zhu YC, Debettes S (2018) Burden of dilated perivascular spaces, an emerging marker of cerebral small vessel disease, is highly heritable. *Stroke* 49: 282–287

160.  Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Beshutz C, Armulik A, Sallstrom J et al (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature* 485: 512–516

161.  Bennett RE, Robbins AB, Hu M, Cao X, Betensky RA, Clark T, Das S, Hyman BT (2018) Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301S transgenic mice and human Alzheimer’s disease. *Proc Natl Acad Sci* 115: E1289–E1298

162.  Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, Sengillo JD, Hillman S, Kong P, Nelson AR et al (2015) GLUT1 reductions exacerbate Alzheimer’s disease vasculo-neuronal dysfunction and degeneration. *Nat Neurosci* 18: 521–530

163.  Koch H, Weber YG (2019) The glucose transporters type 1 (Glut1) syndromes. *Epilepsy Behav* 91: 90–93

164.  Tang M, Gao G, Rueda CB, Yu H, Thibedaux DN, Awano T, Engelsland KM, Sanchez-Quintero M, Yang H, Li F et al (2017) Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein. *Nat Commun* 8: 1–15

165.  Montagné A, Nikolakopoulou AM, Zhao Z, Sagare AP, Si G, Lacz D, Barnes SR, Daianu M, Ramanathan A, Go A et al (2018) Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. *Nat Med* 24: 326–337

166.  Joutel A, Monet-leprêtre M, Gosele C, Barorn-menguy C, Hammes A, Schmidt S, Lemaire-carrette B, Domenga V, Schedl A, Lacombe P et al
